PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2009-10-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 45
- Registration Number
- NCT00143312
- Locations
- 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom
Long Term Study With B2036-PEG
Phase 3
Completed
- Conditions
- Acromegaly
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2008-07-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT00143416
- Locations
- 🇯🇵
Pfizer Investigational Site, Sannomaru-cho, Naka-ku, Nagoya-shi, Japan
To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2008-02-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT00143338
- Locations
- 🇺🇸
Pfizer Investigational Site, San Antonio, Texas, United States
Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2010-04-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 173
- Registration Number
- NCT00143247
- Locations
- 🇺🇸
Pfizer Investigational Site, San Antonio, Texas, United States
Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer
Phase 3
Completed
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2010-02-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 485
- Registration Number
- NCT00143455
- Locations
- 🇨🇳
Pfizer Investigational Site, Taoyuan, Taiwan
Comparing Irinotecan and 5 FU/FA To 5-FU/FA After Resection Of Liver Metastases For Colorectal Cancer
Phase 3
Completed
- Conditions
- Colorectal NeoplasmsLiver Neoplasms
- Interventions
- Drug: Folinic Acid + 5 FU
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2010-09-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 321
- Registration Number
- NCT00143403
- Locations
- 🇬🇧
Pfizer Investigational Site, Surrey, United Kingdom
A 52-Week Placebo-Controlled Study Evaluating the Safety of Varenicline
Phase 3
Completed
- Conditions
- Smoking Cessation
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2007-06-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 375
- Registration Number
- NCT00143299
- Locations
- 🇦🇺
Pfizer Investigational Site, Woodville South, South Australia, Australia
A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation
Phase 3
Completed
- Conditions
- Smoking Cessation
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2007-06-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1005
- Registration Number
- NCT00143364
- Locations
- 🇺🇸
Pfizer Investigational Site, Milwaukee, Wisconsin, United States
A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline for the Maintenance of Smoking Cessation
Phase 3
Completed
- Conditions
- Smoking Cessation
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2007-06-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2000
- Registration Number
- NCT00143286
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
An Open Label Study That Compares Varenicline to Transdermal Nicotine Patch for Smoking Cessation
Phase 3
Completed
- Conditions
- Smoking Cessation
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2007-06-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 730
- Registration Number
- NCT00143325
- Locations
- 🇬🇧
Pfizer Investigational Site, Nottingham, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath